目的:观察沙利度胺联合地塞米松(TD)治疗初治多发性骨髓瘤(MM)的疗效和毒副反应。方法:25例初治MM患者,给予沙利度胺(100mg/d起,每周增加50mg~100mg/d到200mg/d)联合地塞米松40mg/d(d1~4,9~12,17~20),28天为一疗程,至少2个疗程。与既往18例使用VAD方案治疗MM初治患者作对照。结果:观察组25例中,14例部分缓解(56％),6例进步(24％),总有效率80%。对照组18例中,部分缓解13例,进步2例,总有效率83.3%。两组总有效率无显著性差异(P gt;0.05),但主要副作用发生率观察组明显少于对照组(P lt;0.05)。结论:沙利度胺联合地塞米松(TD)治疗多发性骨髓瘤疗效高、副作用少和耐受性好,值得进一步的临床观察和推广。老年患者(年龄 gt;65岁),地塞米松减量应用,可减少副作用,且不影响疗效的发挥。
Citation：
LI Bo,ZHANG JinLin,GAN Maozhou,et al.. Clinical Analysis of Thalidomide Companied Dexamethasone in the Treatment of Patients with Initial Multiple Myeloma. West China Medical Journal, 2009, 24(7): 1736-1739. doi:
Copy
Copyright © the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved
| 1. |
RICHARDSON P, SCHLOSSMAN R, JAGANNATH SRICHARDSON P, et al. Thalidomide for patients with relapse multiple myeloma after highdose chemotherapy and stem cell transplantation:results of an openlabel multicenter phase 2 studies of efficacy, toxicity, and biological activity [J]. Mayo Clin Proc, 2004, 79:875-882.
|
| 2. |
BERNARDESCHI P, DENTICO P, ROSSI S, et al. Chemoresistant myeloma:phase II clinical study with lowdose thalidomide plus highdose dexamethasone [J]. Chemother 2004, 16 (suppl 5):90-93.
|
| 3. |
RAJKUMAR S V, BLOOD E, VESOLE D, et al. Phase III trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group [J]. Clin Oncol, 2006, 24:431-436.
|
| 4. |
张之南,主编.血液病诊断及疗效标准[M]. 第2版.北京:科技出版社,1998:373-380.
|
| 5. |
孙燕,周际昌,主编.临床肿瘤内科手册[M].第4版.北京:人民卫生出版社,2003:102-104.
|
| 6. |
ALEXANIAN R, DIMOPOULOS M A, DELASALLE K, et al. Primary dexamethasone treatment of multiple myeloma [J]. Blood, 1992, 80:887-890.
|
| 7. |
JIMENEZZEPEDA, DOMINGUEZMARTINEZ. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? [J]. Eur J haematol, 2006, 77:239-244.
|
| 8. |
朱兴虎,魏旭东,高全立,等.沙利度胺联合地塞米松治疗初发性多发性骨髓瘤的临床观察.白血病[J].淋巴瘤,2006,15(1):48-49.
|
| 9. |
RAJKUMAR S V, JACOBUS S, CALLANDER N, et al. a randomized trial of lenaldomide plus highdose dexamethasone (rd) versus lenalidomide plus lowdose dexamethasone (RD) in newly diagnosed multiple myeloma (E4A03):a trial coordinated by the Eastern Cooperative Oncology Group[J].Blood,2007,110:31a.abstract 74.
|
- 1. RICHARDSON P, SCHLOSSMAN R, JAGANNATH SRICHARDSON P, et al. Thalidomide for patients with relapse multiple myeloma after highdose chemotherapy and stem cell transplantation:results of an openlabel multicenter phase 2 studies of efficacy, toxicity, and biological activity [J]. Mayo Clin Proc, 2004, 79:875-882.
- 2. BERNARDESCHI P, DENTICO P, ROSSI S, et al. Chemoresistant myeloma:phase II clinical study with lowdose thalidomide plus highdose dexamethasone [J]. Chemother 2004, 16 (suppl 5):90-93.
- 3. RAJKUMAR S V, BLOOD E, VESOLE D, et al. Phase III trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group [J]. Clin Oncol, 2006, 24:431-436.
- 4. 张之南,主编.血液病诊断及疗效标准[M]. 第2版.北京:科技出版社,1998:373-380.
- 5. 孙燕,周际昌,主编.临床肿瘤内科手册[M].第4版.北京:人民卫生出版社,2003:102-104.
- 6. ALEXANIAN R, DIMOPOULOS M A, DELASALLE K, et al. Primary dexamethasone treatment of multiple myeloma [J]. Blood, 1992, 80:887-890.
- 7. JIMENEZZEPEDA, DOMINGUEZMARTINEZ. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? [J]. Eur J haematol, 2006, 77:239-244.
- 8. 朱兴虎,魏旭东,高全立,等.沙利度胺联合地塞米松治疗初发性多发性骨髓瘤的临床观察.白血病[J].淋巴瘤,2006,15(1):48-49.
- 9. RAJKUMAR S V, JACOBUS S, CALLANDER N, et al. a randomized trial of lenaldomide plus highdose dexamethasone (rd) versus lenalidomide plus lowdose dexamethasone (RD) in newly diagnosed multiple myeloma (E4A03):a trial coordinated by the Eastern Cooperative Oncology Group[J].Blood,2007,110:31a.abstract 74.
